Unit
- Regulatory definition: A serious adverse event (SAE) is any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment, as per ICH E6 and 21 CFR 312.32.
- Life-threatening events: An event is life-threatening if the patient was at immediate risk of death at the time of the event. This does not include events that hypothetically might have caused death if more severe. Clear distinction is critical for determining expedited reporting timelines.
- Hospitalization criterion: Hospitalization for elective procedures or pre-existing conditions not worsened by the adverse event typically does not qualify. Only admissions directly caused by the adverse event or prolongations of existing stays meet the SAE definition.
- Persistent disability: Disability refers to a substantial disruption of a person's ability to conduct normal life functions. Temporary muscle aches or minor discomforts do not count. The condition must be significant and prolonged.
- Congenital anomalies: Any congenital abnormality or birth defect discovered in offspring of a subject exposed to a medical product is considered a serious adverse event in the parent, requiring prompt reporting even if the parent experiences no symptoms.
- Other serious situations: Events that may not meet the above criteria but require intervention to prevent one of those outcomes, such as use of emergency surgery to prevent permanent impairment, also qualify as SAEs.
- Expectedness vs. serious: Expectedness is a separate assessment. A known side effect that is consistent with product labeling is still an SAE if it meets seriousness criteria. Both dimensions must be evaluated independently.
- Global harmonization: While core criteria are consistent across ICH regions, local variations exist. For example, some authorities require reporting of events that are medically significant even if not immediately serious. Always consult local regulations.
- Reporting timelines: Fatal or life-threatening SAEs must be reported to regulatory authorities within 7 calendar days of investigator awareness. All other serious events must be reported within 15 calendar days. These expedited reporting requirements ensure rapid identification of potential safety signals.
- Investigator responsibilities: The investigator must immediately report any SAE to the sponsor, document all relevant information in the source records, and follow the protocol's specific reporting procedures. The investigator does not assess causality before reporting; all SAEs must be reported regardless of suspected relationship.
- Causality assessment: Sponsors must evaluate the relationship between the investigational product and each SAE using predefined categories like not related, unlikely, possibly, probably, or definitely related. This assessment, combined with expectedness, determines if the event qualifies as a SUSAR requiring expedited reporting.
Terminology
- Serious Adverse Event (SAE)
- An adverse event that meets regulatory seriousness criteria requiring expedited reporting.
- SUSAR
- Suspected Unexpected Serious Adverse Reaction - an SAE that is both suspected to be related to the product and not listed in the reference safety information.
- Expedited Reporting
- Rapid notification to regulatory authorities within 15 days (or 7 days for fatal/life-threatening events) of investigator awareness.
Quick Revision
- SAE definition includes death, life-threatening events, hospitalization, disability, congenital anomaly, and intervention to prevent permanent impairment.
- Distinguish seriousness (outcome) from expectedness (known vs. unknown) - both are evaluated independently.
- Global harmonization exists but local variations require attention to specific regulatory authority expectations.
- Terminology like SUSAR and expedited reporting are foundational to SAE management processes.